Navigation Links
Marinus Pharmaceuticals Adds Two Life Sciences Veterans to its Board of Directors

BRANFORD, Conn., July 29 /PRNewswire/ -- Marinus Pharmaceuticals, Inc. a developer of drugs to treat serious neurological and psychiatric disorders, today announced the appointment of George F. Horner III of Sofinnova Ventures and Harry T. Rein of Foundation Medical Partners to its Board of Directors.

"We are thrilled to expand our board of directors with George and Harry, both of whom have tremendous track records for advancing drug pipelines, leading pharmaceutical and life sciences companies and in delivering value to stakeholders," said John Krayacich, CEO , president and director of Marinus Pharmaceuticals. "Their expertise will be extremely valuable as we progress our lead product, ganaxolone for epilepsy, through additional clinical trials."

George F. Horner III is a pharmaceutical/biopharmaceutical executive with over 40 years of experience in the industry. Currently, Mr. Horner is an executive-in-residence with Sofinnova Ventures, a leading venture capital firm. Previously, he was CEO of Prestwick Pharmaceuticals, a CNS company that he directed to obtain FDA approval for Tetrabenazine (TBZ), the first drug ever licensed in the United States to treat Huntington's Disease patients. Prior to that, Mr. Horner was CEO of Vicuron Pharmaceuticals, an anti-infective company that he grew from a market value of $12.8 million to a company sold to Pfizer for $1.9 billion. Additionally, he has held numerous executive, general management, business development and marketing/sales positions with Abbott Laboratories and E.R. Squibb across 4 continents, worldwide. Mr. Horner is Chairman of the Board of Creabilis Therapeutics of Luxembourg and a member of the board of Novexel, SA, France.

"I look forward to working with the Marinus team and am impressed by the financing and clinical milestones the company accomplished recently," said Mr. Horner. "I'm especially eager to be a part of a company with positive phase 2a data for a novel first in class antiepileptic drug that will address unmet medical needs for adults with partial onset seizures."

Harry T. Rein, general partner at Foundational Medical Partners, also joins the Marinus board of directors. Rein brings almost 30 years of executive experience to his role at Marinus. Prior to Foundation Medical Partners, Rein was principal founder of Canaan Partners and served for 15 years as founder and general manager of the venture capital investment firm. He also previously served as President and CEO of General Electric Venture Capital Corporation and directed several of GE's lighting businesses as general manager before joining GE Venture Capital Corporation. Rein has also held numerous senior level positions across a broad range of industries including tenures at Transaction Systems, Inc., Gulf Oil Corporation and Polaroid Corporation. He has served on the boards of directors of over 20 public and private entrepreneurial companies, including Cell Pathways, OraPharma (acquired by Johnson & Johnson), National MD (acquired by GE), OmniSonics, GenVec, CardioNet and Spine Wave. Rein also serves as a Trustee of the Cleveland Clinic, Chairman of the Industrial Advisory Board of Cleveland Clinic Innovations and Trustee of the University of Virginia Darden School of Business Foundation.

About Ganaxolone

Ganaxolone is a synthetic neurosteroid and a derivative of the naturally occurring GABA-alpha neuromodulator, allopregnanolone. It is being investigated as a first in class treatment for epilepsy. Ganaxolone has been administered to more than 950 healthy adult volunteers and patients in more than 35 Phase 1 and Phase 2 studies. Early epilepsy studies involved more than 250 patients and generated data supportive of the efficacy and safety of ganaxolone in the treatment of both children and adults suffering from refractory epilepsy (patients who continue to have seizures despite taking multiple anticonvulsant drugs).

Marinus has successfully developed several proprietary and novel patented formulations of ganaxolone.

About Marinus Pharmaceuticals

Marinus is a specialty pharmaceutical company dedicated to the reformulation, development, and commercialization of novel drugs to treat serious neurological, psychiatric, and pain disorders. Marinus is located in Branford, Connecticut. Its investors include Domain Associates, Canaan Partners, Sofinnova Ventures and Foundation Medical Partners. For additional information, please visit the company's Web site at

    John Krayacich                         Shirley Chow
    CEO                                    Media Relations
    Marinus Pharmaceuticals                Porter Novelli Life Sciences
    203-315-5809                           212-601-8308 

SOURCE Marinus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
2. Marinus Pharmaceuticals Raises $20 Million in Series B Financing
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ - ... the request of IIROC on behalf of the Toronto ... this news release there are no corporate developments that ... price. --> --> ... --> . --> Aeterna Zentaris ...
(Date:11/24/2015)... , November 24, 2015 ... market research report "Oligonucleotide Synthesis Market by Product & ... Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & ... by MarketsandMarkets, the market is expected to reach USD ... 2015, at a CAGR of 10.1% during the forecast ...
(Date:11/24/2015)... , ... November 24, 2015 , ... The Academy of ... Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the First–Person ... few years. Many AMA members have embraced this type of racing and several new ...
(Date:11/24/2015)... , November 24, 2015 ... market research report released by Transparency Market Research, the ... at a CAGR of 17.5% during the period between ... Market - Global Industry Analysis, Size, Volume, Share, Growth, ... non-invasive prenatal testing market to reach a valuation of ...
Breaking Biology Technology:
(Date:10/26/2015)... PUNE, India , October 26, ... --> --> ... Forecasts 2015 to 2021 as well ... Analysis 2015-2019 research reports to its ... . ...
(Date:10/26/2015)... 2015  Delta ID Inc., a company focused on ... PC devices, announced its ActiveIRIS® technology powers the iris ... launched by NTT DOCOMO, INC in Japan ... smartphone to include iris recognition technology, after a very ... in May 2015, world,s first smartphone to have this ...
(Date:10/23/2015)... and GOLETA, California , October 23, ... BIOPAC and SensoMotoric Instruments (SMI) announce a mobile plug ... data captured during interactive real-world tasks SensoMotoric ... integration of their established wearable solutions for eye tracking ... gaze behavior captured with SMI Eye Tracking Glasses ...
Breaking Biology News(10 mins):